Relapse, remission, and progression in multiple sclerosis

New England Journal of Medicine

Volumn 343, Issue 20, 2000, Pages 1486-1487

  McDonald, W I ^a  

^a ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD52 ANTIGEN; CONTRAST MEDIUM; GADOLINIUM; NITRIC OXIDE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

CLINICAL TRIAL; CONTRAST ENHANCEMENT; DEMYELINATING DISEASE; DISABILITY; DISEASE COURSE; EDITORIAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; REMISSION;

DISABILITY EVALUATION; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS; RECURRENCE;

EID: 0034676603     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200011163432010     Document Type: Editorial

References (9)

1. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
2. The pathophysiology of multiple sclerosis: The mechanisms underlying the production of symptoms and the natural history of the disease
3. Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: A functional magnetic resonance imaging study
4. Axonal pathology in multiple sclerosis: A historical note
5. Nitric oxide causes axonal degeneration which is exacerbated by impulse activity
6. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
7. Relapses and progression of disability in multiple sclerosis
8. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up
9. The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course